Acurx Pharmaceuticals, Inc. (ACXP)
NASDAQ: ACXP · Real-Time Price · USD
0.9600
-0.0250 (-2.54%)
At close: Nov 13, 2026, 4:00 PM EST
1.010
+0.050 (5.21%)
After-hours: Nov 13, 2026, 7:29 PM EST

Acurx Pharmaceuticals Balance Sheet

Millions USD. Fiscal year is Jan - Dec.

Assets

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Equivalents
9.657.563.717.479.1112.96
Cash & Short-Term Investments
9.657.563.717.479.1112.96
Cash Growth
63.45%103.85%-50.41%-17.97%-29.69%308.10%
Other Receivables
0.040.050.050.13--
Receivables
0.040.050.050.13--
Prepaid Expenses
0.640.090.10.110.260.3
Total Current Assets
10.347.693.867.719.3813.25
Total Assets
10.347.693.867.719.3813.25

Liabilities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Accounts Payable
2.990.01000.030.06
Accrued Expenses
-2.413.243.042.030.78
Total Current Liabilities
2.992.423.243.042.060.84
Total Liabilities
2.992.423.243.042.060.84

Shareholders' Equity

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Common Stock
0.01000.010.010.01
Additional Paid-In Capital
89.1580.5567.9457.8745.9438.95
Retained Earnings
-81.81-75.29-67.32-53.22-38.64-26.55
Shareholders' Equity
7.345.270.624.677.3212.41
Total Liabilities & Equity
10.347.693.867.719.3813.25

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Cash (Debt)
9.657.563.717.479.1112.96
Net Cash Growth
63.45%103.85%-50.41%-17.97%-29.69%316.83%
Net Cash Per Share
2.665.044.5911.8016.8530.36
Filing Date Shares Outstanding
6.062.861.10.790.580.51
Total Common Shares Outstanding
5.882.350.850.720.580.51
Working Capital
7.345.270.624.677.3212.41
Book Value Per Share
1.252.240.726.4512.5824.30
Tangible Book Value
7.345.270.624.677.3212.41
Tangible Book Value Per Share
1.252.240.726.4512.5824.30
SEC Filings: 10-K · 10-Q